• IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here.

    The OTHER forum is HERE so please stop asking.

Pfizer says immunity can drop to 83% within four months in people who got its COVID-19 shot, further bolstering the company case for a booster

ginfreely

Alfrescian
Loyal
By

Jaimy Lee

The drug maker said this week that new data shows effectiveness can decline to about 83.7% four to six months after vaccination​

im-377378

A vial of Pfizer's COVID-19 vaccine.​

AFP VIA GETTY IMAGES
 

ginfreely

Alfrescian
Loyal
The effectiveness of Pfizer’s COVID-19 shot can drop to 83.7% within four to six months after getting the second dose of its vaccine. This is the latest indication that vaccine-induced immunity to the virus can wane and some kind of boost may be necessary in the future.

New research published Wednesday as a preprint indicates that the Pfizer Inc. PFE, +0.05% shot provides 96.2% protection for the first two months, 90.1% effectiveness between the second and fourth months, and between 83.7% of protection for the fourth, fifth, and six months.

“We will need a booster eight to 12 months from the second dose,” Pfizer CEO Albert Bourla said Wednesday, according to a FactSet transcript of the company’s second-quarter earnings call.
 

ginfreely

Alfrescian
Loyal
The drug maker has been making the case for booster shots, citing limited data from its own clinical research and real-world data out of Israel, where Pfizer’s vaccine is the predominant shot in circulation.

“We do see—after six to eight months—more rapid waning concerning infections and mild to moderate symptoms,” Dr. Mikhail Dolsten, Pfizer’s chief scientific officer, said during the call. “Those are likely entirely, or to a large degree, dependent on antibodies and the drop in titer that we alluded to. If you raise it, you may have a good probability to reverse that waning.”

Still, there’s no simple black-and-white answer to whether booster shots are needed at this time.

One, there is no definitive data. The new Pfizer data is the most detailed so far, though the company plans to submit clinical data for a third dose to the Food and Drug Administration in early August.

When speaking to investors this week, company officials attributed waning immunity levels in Israel to the much earlier vaccination campaign that rolled out in that country. (In fact, Israel announcedThursday that a third dose will now be available to people who are at least 60.) Pfizer also mentioned that there will be data in a few months coming out of the U.K., where doses were sometimes spaced out, that indicates “long-lasting protection.”

In addition, we still don’t know which people will need to boost their protection levels. Will the entire vaccinated population need a boost? What if third shots are only necessary for the elderly or people who are immunocompromised? What diagnostic test can be used to assess titer levels before giving a booster? How soon does this all need to happen?
 

ginfreely

Alfrescian
Loyal
“While I cannot predict with certainty the future, I would not be surprised if, similar to flu, that we would need…to boost our vaccine against COVID,” Dolsten said. “Whether this will be on an annual [basis] or based on simple diagnostics that allow it to be boosted at the right time before your risk for infection is high, we need to monitor.”

Either way, it’s a boon for Pfizer, as the legacy drug maker shifts into its new role as a vaccine leader.

Pfizer is expected to generate $33.5 billion in COVID-19 vaccine revenue this year, and Wall Street analysts have already baked boosters into their financial models for Pfizer and BioNTech SE BNTX, +5.04%, which developed the vaccine with Pfizer.

“The largest remaining uncertainty is whether this third boost is simply the third dose in a three-vaccine schedule to achieve lasting, broad protection or is the first of a periodic (annual) boosted vaccine,” SVB Leerink analysts told investors on Thursday.

Moderna Inc. MRNA, +2.30%, which developed the other FDA-authorized mRNA-based COVID-19 vaccine, is also testing booster shots in clinical trials. It has been much quieter in its communication around a third shot. The company is scheduled to share second-quarter earnings on Aug. 5.

Pfizer’s stock is up 16.3% so far this year, while the broader S&P 500 SPX, -0.54% has gained 17.1%.
 

Leongsam

High Order Twit / Low SES subject
Admin
Asset

ginfreely

Alfrescian
Loyal
83% is still an excellent figure. I take the flu jab annually and there are some years when the efficacy of the flu shot is in the low 20s.
I still can’t play the video. Is this the new normal look of video posted on this forum?

65695EAB-D314-4CF4-ABC0-6103EF6FBF53.jpeg
 

in3deep

Alfrescian
Loyal
they just fleecing people now for more $$$ cause they know there are dumb fucks like OYK who will give them business
 

laksaboy

Alfrescian (Inf)
Asset
they just fleecing people now for more $$$ cause they know there are dumb fucks like OYK who will give them business

They have begun to plant the seeds into public consciousness: booster shots are needed. How many, how often and any formula change... no idea yet.

So please don't put up the 'V' sign, act cute and think two shots and it's happily ever after. :biggrin:

176458888_10159338612218686_5798394054759764269_n.jpg
 

ginfreely

Alfrescian
Loyal

ginfreely

Alfrescian
Loyal
https://www.france24.com/en/live-ne...covid-booster-shots-from-september-draft-text

Germany plans Covid booster shots from September: draft text​


Issued on: 01/08/2021 - 17:40
Germany plans to start offering Covid-19 booster shots to the elderly and at-risk from September 1, according to a draft document seen by AFP on Sunday, as concerns grow about the spread of the Delta variant.

The plan also recommends promoting vaccination for those aged 12-17, which would go further than earlier guidance issued by the country's vaccine regulator.

Health Minister Jens Spahn and Germany's 16 regional health ministers are expected to finalise the plans, drawn up by ministry officials, in a meeting Monday.
 

ginfreely

Alfrescian
Loyal
Mobile vaccination teams will be sent into care and nursing homes to offer Pfizer/BioNTech or Moderna booster shots to residents, regardless of which vaccine they had originally, says the document.

Doctors will also be able to administer the booster jab to those who qualify, such as the elderly and people with weakened immune systems.

The text justifies the initiative by citing recent studies showing that protection from infection declines with time, putting vulnerable people at risk again.

Although Germany is currently enjoying relatively low infection rates compared with neighbouring countries, case numbers have been creeping up in recent weeks mainly because of the more contagious Delta variant.

There are also concerns about a slowdown in the country's vaccination rate, with just over 52 percent of the population fully jabbed.

- 'Safe return' to school -

In an effort to get more younger people vaccinated, health ministers want to widen access by opening all the country's vaccination centres to 12- to 17-year olds.

Schools and universities should also offer the jabs, the draft resolution says.

Germany's STIKO vaccine commission disappointed many in June when it officially recommended the vaccine only for 12-17 year olds if they had pre-existing conditions, or lived with people at high risk from Covid.

Although adolescents who don't fall into those categories are still allowed to get vaccinated, in consultation with their parents and doctors, the cautious STIKO guidance has slowed take-up.

Within the European Union, the European Medicines Agency has approved the Pfizer/BioNTech and Moderna shots for all over-12s.

Health Minister Spahn tweeted on Saturday that so far one in five of Germany's 12-17 year olds had received their first coronavirus shot.

"There's enough vaccine for all age groups: anyone who wants to, can get vaccinated," he wrote.

If Spahn and his regional peers sign off on the draft text, their decision to encourage all adolescents to roll up their sleeves would essentially see them bypass STIKO, which has said it needs more data before issuing a more general recommendation.

According to the draft, getting children and teenagers vaccinated could "contribute significantly to a safe return to classrooms after the summer holidays".

Germany's Robert Koch health institute reported 2,097 new daily coronavirus cases on Sunday and one death.

Since the pandemic started, Germany has recorded more than 3.7 million cases and 91,659 deaths.
 
Top